• Novartis received a positive European regulatory committee opinion for Cosentyx in adolescents aged 12 and older with hidradenitis suppurativa.
• The recommendation covers active moderate to severe disease inadequately controlled by conventional systemic therapy.
• Existing clinical evidence showed weight-based adolescent dosing provided drug exposure generally comparable to adults; supporting evidence included adult trials and pediatric data.
• A European Commission decision is expected within approximately two months.
• If cleared, Cosentyx would become Europe's only IL-17A inhibitor for adolescent HS, its first innovative biologic option in nearly a decade.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.